secwatch.observer — SEC 8-K summary
======================================

Issuer:     NextCure, Inc. (NXTC)
CIK:        0001661059
Form:       8-K
Filed at:   2026-09-25T20:10:39+00:00
Accession:  0001104659-26-110971
Event type: litigation
Sentiment:  negative
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

NextCure seeks Delaware court validation of 2025 reverse split tied to Avere merger
--------------------------------------------------------------------------------

- NextCure filed a Section 205 petition on Sept. 14, 2026, in Delaware Court of Chancery seeking validation of its 1:12 reverse split filed July 10, 2025.
- The 2025 reverse split drew 18,166,577 votes for, 2,028,946 against and 6,613 abstentions; 64.76% of outstanding shares backed it, short of the 66 2/3% supermajority.
- The Delaware Court of Chancery scheduled a hearing for Nov. 6, 2026, at 3:00 p.m. ET; stockholder opposition submissions are due by Oct. 27, 2026, to the Register in Chancery.
- NextCure plans a 2026 reverse split under the supermajority standard tied to its Avere Therapeutics combination; failure could delay or block that merger.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661059/000110465926110971/0001104659-26-110971-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661059/000110465926110971/nxtc-20260921x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-110971

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer